Shukun is a Chinese startup that uses AI to power medical imaging diagnosis. The company develops AI-driven tools for diagnosing medical images. It secured 700 million yuan (about $108 million) in a new funding round. The round was led by Goldman Sachs and Primavera Capital Group. The funding was announced on Monday. The article does not provide operating metrics, use of proceeds, or details on other investors. Shukun is a Beijing-based artificial intelligence startup focused on medical diagnostics. Its core product, CoronaryDoc, is an assisting software launched in early 2018 that helps doctors diagnose heart disease using visual recognition technologies. By the end of September 2019 CoronaryDoc had been used on a trial basis in more than 100 hospitals in China. In February the company launched an AI system to help diagnose COVID-19, which has been deployed in multiple hospitals including Wuhan Zhongxin Hospital. Shukun plans to use new funding to expand application of its AI technologies for cardiovascular and neurological diseases and cancer detection across hospitals nationwide, with emphasis on grass‑root medical institutions. The company was founded in 2017.

Total raised

$137M

Funding rounds

2

Latest round

Equity

Latest activity

Aug 2021